toripalimab
shanghai junshi bioscience,coherus biosciences
['urothelial', 'toripalimab', 'blcsm', 'polaris']
after 2-years in the phase 2 #polaris-3 clinical trial, #toripalimab demonstrated clinical activity in patients with #urothelialcarcinoma. #uc #blcsm #asco22 
Oncology news and insights from leading researchers and cancer centers.